Evidence
Biochim Biophys Acta Mol Basis Dis. 2024 Feb 28;1870(4):167102. doi: 10.1016/j.bbadis.2024.167102. Online ahead of print.
ABSTRACT
Non-alcoholic steatohepatitis (NASH) is a pathogenic stage of the broader non-alcoholic fatty liver disease (NAFLD). Histological presentation of NASH includes hepatocyte ballooning, macrophage polarization, ductular reaction, and hepatic stellate cell (HSCs) activation. At a cellular level, a heterogenous population of cells such as hepatocytes, macrophages, cholangiocytes, and HSCs undergo dramatic intra-cellular changes in response to extracellular triggers, which are termed “cellular plasticity. This dynamic switch in the cellular structure and function of hepatic parenchymal and non-parenchymal cells and their crosstalk culminates in the perpetuation of inflammation and fibrosis in NASH. This review presents an overview of our current understanding of cellular plasticity in NASH and its molecular mechanisms, along with possible targeting to develop cell-specific NASH therapies.
PMID:38422712 | DOI:10.1016/j.bbadis.2024.167102
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
🌐 90 Days
VR Related Evidence Matrix
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
- Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines
- Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- Terf2ip deficiency accelerate non-alcoholic steatohepatitis through regulating lipophagy and fatty acid oxidation via Sirt1/ AMPK pathway
- Protective effects of dopamine against non-alcoholic steatohepatitis via inhibiting p65 pathways in vivo and in vitro
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Vitamin D(3) exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in Sod1 knockout mice: a comparative study of two forms of vitamin D
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- Role of resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, in managing non-alcoholic steatohepatitis: a systematic review and meta-analysis
- Lipidomic signatures discriminate subtle hepatic changes in the progression of porcine non-alcoholic steatohepatitis
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Ablation of histone methyltransferase Suv39h2 in hepatocytes attenuates NASH in mice
- Potent Efficacy of 3-Amino-4-hydroxy Benzoic Acid, a Small Molecule Having Anti-fibrotic Activity, in a Mouse Model of Non-alcoholic Steatohepatitis
- The relationship and diagnostic efficacy of N-terminal propeptide type III collagen in pathological changes associated with non-alcoholic steatohepatitis
- Morroniside delays the progression of non-alcoholic steatohepatitis by promoting AMPK-mediated lipophagy
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Emerging roles of RNA-binding proteins in fatty liver disease
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- miR-519a-3p, found to regulate cellular prion protein during Alzheimer's disease pathogenesis, as a biomarker of asymptomatic stages
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Periportal macrophages protect against commensal-driven liver inflammation
- Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARalpha and suppressing HIF1
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria
- Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- Outcomes and risk factors for mortality in clostridioides difficile infection in patients with NAFLD and NASH
- Mimicking chronic alcohol effects through a controlled and sustained ethanol release device
- From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
- Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice
- Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH
- Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An…
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- NASH triggers cardiometabolic HFpEF in aging mice
- 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine-choline-deficient diet and Western diet mouse models
- Bacteroides and NAFLD: pathophysiology and therapy
- Enhanced cellular therapy: revolutionizing adoptive cellular therapy
- Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort
- The lack of PPARalpha exacerbated the progression of non-alcoholic steatohepatitis in mice with spleen deficiency syndrome by triggering an inflammatory response
- The transcription factor ZNF469 regulates collagen production in liver fibrosis
- A Novel Combination Therapy Targets Sonic Hedgehog Signaling by the Dual Inhibition of HMG-CoA Reductase and HSP90 in Rats with Non-Alcoholic Steatohepatitis
Evidence Blueprint
Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
🌐 365 Days
VR Related Evidence Matrix
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Antifibrotic activity of carbon quantum dots in a human in vitro model of non-alcoholic steatohepatitis using hepatic stellate cells
- Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- The role of N6-methyladenosine in macrophage polarization: A novel treatment strategy for non-alcoholic steatohepatitis
- Targeting Extracellular RNA Mitigates Hepatic Lipotoxicity and Liver Injury in NASH
- Effect of Distinct ECM Microenvironments on the Genome-Wide Chromatin Accessibility and Gene Expression Responses of Hepatic Stellate Cells
- Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage
- Bone marrow monocytes sustain NK cell-poiesis during non-alcoholic steatohepatitis
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
- MiR-552-3p Regulates Multiple Fibrotic and Inflammatory genes Concurrently in Hepatic Stellate Cells Improving NASH-associated Phenotypes
- Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metabolism
- Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma
- Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells
- Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
- Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD
- A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH)
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Mitochondrial- and NOX4-dependent antioxidant defence mitigates progression to non-alcoholic steatohepatitis in obesity
- FABP4 in LSECs promotes CXCL10-mediated macrophage recruitment and M1 polarization during NAFLD progression
- Gut microbe and hepatic macrophage polarization in non-alcoholic fatty liver disease
- Identification of pyroptosis-related gene signature in nonalcoholic steatohepatitis
- Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis
- Mitigation of non-alcoholic steatohepatitis via recombinant Orosomucoid 2, an acute phase protein modulating the Erk1/2-PPARγ-Cd36 pathway
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease
- Miniseries: Established pharmacological targets for NASHFXR agonists in NASH treatment
- NAFLD and NASH: etiology, targets and emerging therapies
- "Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Non-Alcoholic Steatohepatitis in Mice"
- Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in Mice
- The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers
- Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo
- Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice
- FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1
- Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Exercise ameliorates lipid droplet metabolism disorder by the PLIN2-LIPA axis-mediated lipophagy in mouse model of non-alcoholic fatty liver disease
- NLRP3 inflammasome in hepatic diseases: A pharmacological target
- Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
- Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- CD38 Inhibition Protects Fructose-Induced Toxicity in Primary Hepatocytes
- Insights of mitochondrial involvement in alcoholic fatty liver disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model
- Macrophage specific restoration of the Nrf2 gene in whole-body knockout mice ameliorates steatohepatitis induced by lipopolysaccharide from Porphyromonas gingivalis through enhanced hepatic clearance
- Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives
- Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- A CDAHFD-induced mouse model mimicking human NASH in the metabolism of hepatic phosphatidylcholines and acyl carnitines